Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 792-799

  Ghofrani, H A ^a   Hoeper, M M ^b   Halank, M ^c   Meyer, F J ^d   Staehler, G ^e   Behrf, J ^f   Ewert, R ^g   Weimann, G ^h   Grimminger, F ^a  

^a UNIVERSITY HOSPITAL GIESSEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e Medical Clinic I   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF GREIFSWALD   (Germany)

^h BAYER PHARMA AG   (Germany)

Author keywords

Chronic thromboembolic pulmonary hypertension; Clinical study; Phase II; Pulmonary arterial hypertension; Riociguat; Soluble guanylyl cyclase

Indexed keywords

AMLODIPINE; BOSENTAN; DILTIAZEM; FELODIPINE; FUROSEMIDE; GUANYLATE CYCLASE ACTIVATOR; HYDROCHLOROTHIAZIDE; LERCANIDIPINE; NIFEDIPINE; NITRENDIPINE; PHENPROCOUMON; PIRETANIDE; RIOCIGUAT; SPIRONOLACTONE; TORASEMIDE; UNCLASSIFIED DRUG; VERAPAMIL; XIPAMIDE;

ADULT; AGED; ARTICLE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; EXERCISE; FATIGUE; FEMALE; GASTROINTESTINAL INFECTION; HUMAN; HYPOTENSION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SYNCOPE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; AGED; EXERCISE; FEMALE; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZOLES; PYRIMIDINES; SAFETY; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 77956664858     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00182909     Document Type: Article

References (21)

1. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
2. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
3. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
4. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-1030.
5. Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007; 30: 1103-1110.
6. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177: 1122-1127.
7. Bresser P, Pepke-Zaba J, Jais X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc 2006; 3: 594-600.
8. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006; 113: 2011-20.
9. Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. Eur Respir Rev 2009; 18: 24-28.
10. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 2127-2134.
11. Schermuly R, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008; 32: 881-891.
12. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. Chem Med Chem 2009; 4: 853-865.
13. Frey R, Mück W, Unger S, et al. Single-dose pharmacokinetics, tolerability and safety of the soluble guanylate cyclase stimulator BAY 63-2521; an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48: 926-934.
14. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009; 33: 785-792.
15. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
16. Tueller C, Stricker H, Soccal P, et al. Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly 2008; 138: 379-384.
17. Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007; 8: 2247-2265.
18. Frey R, Mück W, Kirschbaum N, et al. Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). BMC Pharmacol 2009; 9: Suppl. 1, P15.
19. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1182.
20. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
21. Halpern SD, Doyle R, Kawut SM. The ethics of randomized clinical trials in pulmonary arterial hypertension. Proc Am Thorac Soc 2008; 5: 631-635.